Welcome to our dedicated page for Editas Medicine SEC filings (Ticker: EDIT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Editas Medicine, Inc. (Nasdaq: EDIT) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures filed with the U.S. Securities and Exchange Commission. As a clinical-stage gene editing company focused on in vivo CRISPR/Cas12a and CRISPR/Cas9 medicines, Editas uses current reports on Form 8-K and other periodic filings to communicate material events, program updates, collaborations, and financial results to investors.
Through its 8-K filings, Editas Medicine furnishes press releases announcing quarterly financial results, cash runway expectations, and business highlights. These documents describe research and development expenses, collaboration and other research revenues, restructuring and impairment charges, and the company’s view of its ability to fund operating expenses and capital expenditure requirements over a multi-year period. They also outline key risk considerations and refer readers to the company’s Annual Report on Form 10-K and subsequent filings for detailed risk factors.
Filings also summarize important scientific and pipeline milestones. For example, Editas has used 8-K reports to describe the nomination of EDIT-401 as its lead in vivo development candidate for hyperlipidemia, preclinical proof-of-concept data demonstrating approximately 90% LDL-C reduction in non-human primates and mice, and the therapeutic strategy of using CRISPR/Cas9 with dual guide RNAs and lipid nanoparticle delivery to upregulate LDLR. Other filings discuss in vivo proof-of-concept data for EDIT-401 presented at major gene and cell therapy conferences.
Investors can review these SEC filings to understand how Editas Medicine reports the status of its in vivo HSC program for sickle cell disease and beta thalassemia, its collaboration with Bristol Myers Squibb on T cell medicines, and payments under its license agreement with Vertex Pharmaceuticals. On Stock Titan, AI-powered tools can help summarize lengthy filings, highlight key sections related to EDIT-401, cash runway, collaborations, and program changes, and make it easier to interpret complex technical and financial disclosures without reading every line of each document.
Editas Medicine used this report to highlight a new in vivo gene-editing candidate, EDIT-401, designed to treat hyperlipidemia by editing the LDLR gene to increase LDL receptor protein and lower LDL cholesterol. In non-human primates, a single dose produced about a 90 percent mean reduction in LDL-C across four dose levels and at least a six-fold mean increase in liver LDLR protein, with no adverse effects reported and transient liver enzyme elevations resolving within one week.
The company plans to prioritize EDIT-401, aiming to submit an IND or CTA by mid-2026 and to achieve in vivo human proof-of-concept data by the end of 2026, while continuing earlier work on hematopoietic stem cell and other cell-type programs. It reaffirmed that existing cash, cash equivalents, marketable securities, and retained portions of payments from its Vertex license are expected to fund operations and capital needs into the second quarter of 2027.
Editas Medicine (EDIT) Form 144 notice reports a proposed sale of 7,000 shares of Common Stock to be executed through ETrade on 09/03/2025 on Nasdaq with an aggregate market value of $19,110.00. The filing shows these shares were acquired on 09/02/2025 through restricted stock unit vesting (equity compensation), with 11,294 shares listed as acquired on that date. The filing also discloses a sale by Gilmore O'Neill of 15,192 shares on 06/03/2025 for gross proceeds of $26,195.57. The notice includes the standard representation that the seller does not possess undisclosed material adverse information about the issuer.
Editas Medicine (EDIT) submitted a Form 144 disclosing a proposed sale of 800 shares of common stock with an aggregate market value of $2,184, listed for sale on Nasdaq and dated approximately 09/03/2025. The securities were acquired on 09/02/2025 through restricted stock unit vesting (1,550 shares acquired) and payment was in the form of equity compensation. The filing also reports two prior sales by the same person in the past three months: 726 shares on 06/03/2025 ($1,251.84) and 5,121 shares on 07/31/2025 ($12,756.92). The form includes the standard attestation that the seller is unaware of undisclosed material adverse information.
Editas Medicine (EDIT) reported a net loss of $129.3 million for the six months ended June 30, 2025, or $1.54 per share, widening its accumulated deficit to $1.6 billion. Total assets fell to $210.6 million from $341.6 million at year-end 2024, and stockholders' equity declined to $19.2 million. Cash and cash equivalents were $138.5 million and marketable securities were $39.9 million, totaling $178.5 million in liquid investments.
The company discontinued its ex vivo reni-cel program and initiated a workforce reduction of approximately 180 positions (about 65%), recording $66.9 million of restructuring and impairment charges in the six months and $79.2 million since the December 2024 decision. Editas received $57.0 million from DRI under a sale-of-future-revenues agreement (accounted for as debt; estimated effective interest rate 15.1%, liability $56.7 million) and has an amended ATM facility with $141.4 million remaining capacity after $8.6 million of sales. Management expects existing cash, cash equivalents and marketable securities to fund operations for at least twelve months from the consolidated financial statement issuance date.
Editas Medicine announced that it has furnished a press release reporting its financial results for the fiscal quarter ended June 30, 2025 and other business highlights. The press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is expressly furnished, not filed, so the numerical results and business detail are contained in that exhibit rather than in the body of the filing.
Editas Medicine insider transaction by SVP & Chief Financial Officer Amy Parison: The filing reports a non-discretionary sale of 679 shares of common stock at $2.58 per share, executed under a durable automatic sales instruction plan. The sale satisfied tax withholding obligations arising from the vesting of restricted stock units and is explicitly described as not a discretionary trade by the reporting person.
After the reported sale the reporting person beneficially owned 16,827 shares directly. The filing identifies the issuer as Editas Medicine, Inc. and classifies the report as a Form 4 statement of changes in beneficial ownership.